Inflammation and its resolution is under-studied in medicine despite being essential for
understanding the development of chronic inflammatory disease. In this review article, we …

Background Selective patient recruitment can produce discrepancies between clinical trial
results and real-world effectiveness. Methods A systematic literature review and meta …

Objective We aimed to provide an evidence-supported update of the ECCO-ESPGHAN
guideline on the medical management of paediatric Crohn's disease [CD]. Methods We …

Background & Aims There is debate over whether patients with inflammatory bowel
diseases (IBD) treated with biologics that are not tumor necrosis factor antagonists (such as …

Ulcerative colitis (UC), a relapsing-remitting chronic inflammatory bowel disease (IBD), has
a variable natural course but potentially severe disease course. Since the development of …

The biologic antitumor necrosis factor alpha (anti-TNFα) agents have revolutionised the
treatment of inflammatory bowel disease (IBD). However, some patients experience primary …

Abstract Background and Aims Many observational studies on the use of vedolizumab [VDZ]
in patients with Crohn's disease [CD] and ulcerative colitis [UC] have been published in the …

Background: Prospectively and systematically collected real-world data on vedolizumab are
scarce. We aimed to assess the long-term clinical effectiveness of vedolizumab in …

Background Real-life data on vedolizumab effectiveness in inflammatory bowel disease
(IBD) are still emerging. Data on the comparative safety of the gut selective profile are of …

The advent of monoclonal antibody therapies has revolutionised inflammatory bowel
disease (IBD) treatment and delivered great benefits to patients. The optimal use of this …